CX-516

CX-516

Pharmacokinetic data
Elimination half-life	45 minutes
Identifiers
IUPAC name 6-(Piperidin-1-ylcarbonyl)quinoxaline
JSmol)	Interactive image
SMILES O=C(c2cc1nccnc1cc2)N3CCCCC3
InChI InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 Y Key:ANDGGVOPIJEHOF-UHFFFAOYSA-N Y
(verify)

CX-516 is an

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as

See also

• AMPA receptor positive allosteric modulator

References

• Danysz W (July 2002). "CX-516 Cortex pharmaceuticals". Current Opinion in Investigational Drugs. 3 (7): 1081–8.
  PMID 12186271
  .